Curr Probl Cardiol. 2013 Oct;38(10):417-55. doi: 10.1016/j.cpcardiol.2013.08.001.
Congenital long QT syndrome (LQTS) is a genetically heterogeneous group of heritable disorders of myocardial repolarization linked by the shared clinical phenotype of QT prolongation on electrocardiogram and an increased risk of potentially life-threatening cardiac arrhythmias. At the molecular level, mutations in 15 distinct LQTS-susceptibility genes that encode ion channel pore-forming α-subunits and accessory β-subunits central to the electromechanical function of the heart have been implicated in its pathogenesis. Over the past 2 decades, our evolving understanding of the electrophysiological mechanisms by which specific genetic substrates perturb the cardiac action potential has translated into vastly improved approaches to the diagnosis, risk stratification, and treatment of patients with LQTS. In this review, we describe how our understanding of the molecular underpinnings of LQTS has yielded numerous clinically meaningful genotype-phenotype correlations and how these insights have translated into genotype- and phenotype-guided approaches to the clinical management of LQTS.
先天性长 QT 综合征(LQTS)是一组遗传性心肌复极障碍的基因异质性疾病,其特征为心电图 QT 延长和潜在危及生命的心律失常风险增加。在分子水平上,编码离子通道孔形成α亚单位和辅助β亚单位的 15 个不同的 LQTS 易感性基因的突变与心脏机电功能的中心有关,这些突变与疾病的发病机制有关。在过去的 20 年中,我们对特定遗传底物扰乱心脏动作电位的电生理机制的理解不断发展,这已经转化为对 LQTS 患者的诊断、风险分层和治疗的极大改进方法。在这篇综述中,我们描述了我们对 LQTS 分子基础的理解如何产生了许多具有临床意义的基因型-表型相关性,以及这些见解如何转化为基于基因型和表型的 LQTS 临床管理方法。